Nuron enters into licensing agreement for Amyloid Beta 42 DNA vaccine

Under the agreement, Nuron is responsible for development and commercialization of the vaccine. Financial terms of the agreement have not been disclosed.

The DNA vaccine, which contains a piece of the gene coding for the amyloid beta protein, stimulates an immune response in which antibodies that bind to and reduce amyloid beta are produced.

Nuron Biotech chief executive officer and founder Shankar Musunuri said: "This unique, promising vaccine candidate brings more opportunity to our pipeline and is one of the most promising new advances to improve the lives of Alzheimer’s patients worldwide."